Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib and acetylsalicylic acid, or a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof or a polymorph thereof for treating, preventing or managing diseases and conditions including hyperproliverative disorders such as cancer in humans and other mammals.
Type:
Grant
Filed:
September 23, 2013
Date of Patent:
January 26, 2021
Assignees:
BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AG
Abstract: Disclosed are compounds and compositions that modulate cannabinoid receptors, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors. This disclosure is directed to methods of treating cannabinoid dependence, neuropathy, inflammation, glaucoma, a neurodegenerative disorder, a motor function disorder, a gastrointestinal disorder, hypothermia, emesis, loss of appetite, or anorexia associated with AIDS.
Type:
Grant
Filed:
January 7, 2019
Date of Patent:
January 5, 2021
Assignee:
NORTHEASTERN UNIVERSITY
Inventors:
Alexandros Makriyannis, Ganeshsingh A. Thakur, Rishi Sharma
Abstract: New uses of hypoestoxide, its derivatives and related compounds for treatment and prevention of neurodegenerative diseases (e.g. Parkinsons disease, Alzheimers disease, Huntingtons disease) are described. More specifically, the invention relates to methods for treating various neurodegenerative diseases through administration of hypoestoxide, its derivatives and related compounds, or a combination thereof to a subject with a neurodegenerative disease such that the symptoms of the disease are treated or at least partially alleviated. Furthermore, the present invention further provides methods of preventing the development of neurodegenerative diseases in individuals who are predisposed to developing a neurodegenerative disease over time.
Type:
Grant
Filed:
February 3, 2016
Date of Patent:
December 8, 2020
Assignee:
IMMUNE MODULATION, INC.
Inventors:
Howard Cottam, Emmanuel Ojo-Amaize, Emeka Nchekwube, Olusola Oyemade
Abstract: The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors as therapeutics and imaging agents. The present disclosure also relates to the use of targeting conjugates of carbonic anhydrase IX inhibitors in imaging methods and cancer therapy.
Type:
Grant
Filed:
March 16, 2017
Date of Patent:
December 8, 2020
Assignee:
Endocyte Inc.
Inventors:
Christopher P. Leamon, Iontcho R. Vlahov, Jonathan M. Shillingford, Paul J. Kleindl
Abstract: Provided are salts of (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine and various of crystal forms thereof, and compositions, medicaments, pharmaceutically acceptable formulations thereof, and methods of making same. In addition, provided are compounds comprising specific particle size distributions of crystalline (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine HCl and methods of making and modulating the particle size distributions.
Type:
Grant
Filed:
February 15, 2019
Date of Patent:
October 27, 2020
Assignee:
Sunovion Pharmaceuticals Inc.
Inventors:
Andrea Bauer, Xiaoxia Chen, Shahla Jamzad, Robert Joseph Prytko, Michael Joseph Sizensky, Haitao Zhang
Abstract: A method of producing a compounded medication may include formulating a compounded transdermal cream that includes combining a diclofenac sodium solution and a lidocaine and prilocaine cream. The diclofenac sodium solution may be combined in an amount providing a diclofenac concentration of between approximately 0.1% and approximately 0.75% by weight of the compounded transdermal cream. The lidocaine and prilocaine cream may be combined in an amount providing an approximate equivalent concentration of each of lidocaine and prilocaine between approximately 1.5% and approximately 2.25% by weight of the compounded transdermal cream.
Abstract: The invention includes a method of treating or preventing a Staphylococcus infection in a mammal or avian species in need thereof. The methods comprise administering to the mammal or avian species a therapeutically effective amount of fosmidomycin. In certain embodiments, the methods treat or prevent a drug-resistant Staphylococccus infection.
Type:
Grant
Filed:
July 21, 2017
Date of Patent:
September 15, 2020
Assignee:
The Trustees of The University of Pennsylvania
Inventors:
Daniel P. Beiting, Ana M. Misic, Shelly C. Rankin
Abstract: A novel therapeutic agent and novel anti-HTLV-1 drug for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is provided. A substance capable of inhibiting tyrosine kinase encoded by the ABL1 gene is contained as an active ingredient.
Abstract: Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1 to R6, X1 to X4, and n are the same as defined in claim 1.
Type:
Grant
Filed:
April 23, 2018
Date of Patent:
September 8, 2020
Assignee:
YUNGJIN PHARM CO., LTD.
Inventors:
Whee Seong Lee, Mi Jung Lee, Bo Jung Kim, Tae Cheul Roh, Seung Hoon Lee, Kyu Dae Lee, You-Hui Lee, Tae Hwan Kwak
Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I).
Type:
Grant
Filed:
July 11, 2018
Date of Patent:
September 1, 2020
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Jongwon Lim, Xianhai Huang, Ronald D. Ferguson, Wei Zhou, Christopher W. Boyce, Phieng Siliphaivanh, David J. Witter, Milana M. Maletic, Joseph A. Kozlowski, Kevin J. Wilson
Abstract: The present invention is directed to antiviral compositions that provide efficacy against non-envelope viruses such as noroviruses. The antiviral compositions comprise an alkyl 2-hydroxycarboxylic acid and an effective amount of a sulfonated surfactant. The composition may be used as a topical on human skin, as a hand sanitizer or as a hard surface cleaning composition.
Type:
Grant
Filed:
September 29, 2017
Date of Patent:
August 11, 2020
Assignee:
ECOLAB USA INC.
Inventors:
Daniel E. Pedersen, Hilina Emiru, Carter Martin Silvernail
Abstract: Uses of acyl-homoserine lactone compounds are described. In particular, uses of acyl-homoserine lactone compounds as anti-thrombotic agents, to inhibit platelets from becoming hypersensitive, and/or to prevent thrombosis, are described.
Type:
Grant
Filed:
December 12, 2018
Date of Patent:
July 7, 2020
Assignee:
The University of Toledo
Inventors:
Randall G. Worth, Glenn R. Westphal, Brenton R. Keeley, Leah M. Wuescher
Abstract: There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing a disease or disorder, which disease or disorder is amenable to treatment or prevention by the inhibition of thrombin.
Type:
Grant
Filed:
March 27, 2018
Date of Patent:
May 19, 2020
Assignee:
VERSEON CORPORATION
Inventors:
Kevin Michael Short, Son Minh Pham, David Charles Williams, Somalee Datta
Abstract: Provided herein is an ophthalmic composition including a therapeutic active agent and an anti-inflammatory agent, in which the active agent is at least about 0.01% w/v of chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof. Methods for treating or preventing ocular disease or infection in a subject in need thereof are also provided. The method may include administering to an eye of a subject an ophthalmic composition including chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof, and an anti-inflammatory agent. The chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof and the anti-inflammatory agent are present in an amount effective to treat or prevent the ocular disease or infection in a subject in need thereof.
Abstract: The invention relates to the selective targeting of specific ?2 adrenergic receptor subtypes for facilitating and also restoring standing and walking in a subject affected by spinal cord disorders, in particular spinal cord injury. In particular, the improvement of locomotion by targeting specific receptor subtypes can be achieved by stimulation of the ?2c receptor subtype using an ?2c specific agonist or by blocking the ?2a receptor subtype using ?2a antagonists. A combination of an ?2c agonist and an ?2a antagonist is also provided for a synergistic effect. Alternatively, a large ?2 agonist can be used in combination with an ?2a antagonist to achieve specific stimulation of the ?2c receptor. Pharmaceutical compositions, kit-of-parts and therapeutic systems comprising said agonists/antagonists as active agents are objects of the present invention.
Type:
Grant
Filed:
June 27, 2014
Date of Patent:
April 28, 2020
Assignee:
ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL)
Inventors:
Grégoire Courtine, Quentin Barraud, Pavel Musienko
Abstract: There is provided a method of controlling filbertworm capable of reducing the number of release positions without changing a dosage amount per unit area. More specifically, there is provided a method of controlling filbertworm comprising the step of: providing E,E-8,10-dodecadienyl acetate or a composition comprising 80% by weight or more of E,E-8,10-dodecadienyl acetate at 1 to 100 release positions/ha to release the E,E-8,10-dodecadienyl acetate at a release rate of from 0.01 to 5 g/day/ha for mating disruption.
Abstract: There are provided 5,6-dihydro-4H-dithieno[3,2-b:2?,3?-d]azepine derivatives(as defined in the disclosure) which are useful in the treatment of RSV infection and for the prevention of disease associated with RSV infection.
Type:
Grant
Filed:
April 7, 2017
Date of Patent:
April 21, 2020
Assignee:
PULMOCIDE LIMITED
Inventors:
Simon Fraser Hunt, Stuart Thomas Onions, Vladimir Sherbukhin, Euan Alexander Fraser Fordyce, Jennifer Claire Thomas, Peter John Murray, Matthew Stephen Coates, Daniel William Brookes, Kazuhiro Ito, Peter Strong
Abstract: Provided herein is an ophthalmic composition including a therapeutic active agent and an anti-inflammatory agent, in which the active agent is at least about 0.01% w/v of chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof. Methods for treating or preventing ocular disease or infection in a subject in need thereof are also provided. The method may include administering to an eye of a subject an ophthalmic composition including chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof, and an anti-inflammatory agent. The chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof and the anti-inflammatory agent are present in an amount effective to treat or prevent the ocular disease or infection in a subject in need thereof.
Abstract: A method for producing monovalent unsaturated free fatty acids having 20 and/or 22 carbons or low-grade alcohol esters thereof, said method involving the following: obtaining free fatty acids or low-grade alcohol esters through the hydrolysis or alcoholysis of oils and fats derived from marine products; carrying out distillation on the free fatty acids or low-grade alcohol esters, and reducing the concentration of fatty acids with 18 or less carbons in the low-grade alcohol esters or free fatty acids; and collecting fractions of monovalent unsaturated free fatty acids having 20 and/or 22 carbons or low-grade alcohol esters thereof by column chromatography based on reversed-phase distribution.